Activation of adenosine receptors improves renal antioxidant status in diabetic Wistar but not SHR rats

Upsala Journal of Medical Sciences

Volumn 119, Issue 1, 2014, Pages 10-18

  Patinha, Daniela ^a,b   Afonso, Joana ^a   Sousa, Teresa ^a   Morato, Manuela ^a,b   Albino Teixeira, António ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Adenosine; Angiotensinogen; Hydrogen peroxide; Hyperglycemia; Kidney; Systolic blood pressure

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ANGIOTENSINOGEN; ANTIOXIDANT; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE;

ANIMAL; ARTICLE; BLOOD PRESSURE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; KIDNEY; MALE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; URINE; WISTAR RAT;

ANGIOTENSINOGEN; ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; HYDROGEN PEROXIDE; KIDNEY; MALE; OXIDATIVE STRESS; PURINERGIC P1 RECEPTOR AGONISTS; RATS; RATS, INBRED SHR; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RECEPTORS, PURINERGIC P1;

EID: 84894105502     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2013.851748     Document Type: Article

References (55)

1. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-13.
2. Mori T, Ogawa S, Cowely AW Jr, Ito S. Role of renal medullary oxidative and/or carbonyl stress in salt-sensitive hypertension and diabetes. Clin Exp Pharmacol Physiol. 2012;39:125-31.
3. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-87.
4. ChengJT,ChiTC, LiuIM.ActivationofadenosineA1receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats. Auton Neurosci. 2000;83:127-33.
5. Dong Q, Ginsberg HN, Erlanger BF. Overexpression of the A1 adenosine receptor in adipose tissue protects mice from obesity-related insulin resistance. Diabetes Obes Metab. 2001; 3:360-6.
6. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J. 2007;21:2379-88.
7. Andersson O, Adams BA, Yoo D, Ellis GC, Gut P, Anderson RM, et al. Adenosine signaling promotes regeneration of pancreatic beta cells in vivo. Cell Metab. 2012;15: 885-94.
8. Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev. 2011;63:1-34.
9. Vallon V, Schroth J, Satriano J, Blantz RC, Thomson SC, Rieg T. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol. 2009;111:p30-8.
10. Sallstrom J, Carlsson PO, Fredholm BB, Larsson E, Persson AE, Palm F. Diabetes-induced hyperfiltration in adenosine A(1)-receptor deficient mice lacking the tubuloglomerular feedback mechanism. Acta Physiol (Oxf). 2007;190: 253-9.
11. Faulhaber-Walter R, Chen L, Oppermann M, Kim SM, Huang Y, Hiramatsu N, et al. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol. 2008;19:722-30.
12. Awad AS, Huang L, Ye H, Duong ET, Bolton WK, Linden J, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol. 2006;290:F828-37.
13. Elsherbiny NM, Abd El Galil KH, Gabr MM,Al-GayyarMM, Eissa LA, El-Shishtawy MM. Reno-protective effect of NECA in diabetic nephropathy: implication of IL-18 and ICAM-1. Eur Cytokine Netw. 2012;23:78-86.
14. Chen YF, Li PL, Zou AP. Oxidative stress enhances the production and actions of adenosine in the kidney. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1808-16.
15. Husain K, Somani SM. Interaction of exercise and adenosine receptor agonist and antagonist on rat heart antioxidant defense system. Mol Cell Biochem. 2005;270:209-14.
16. Zhang Y, Handy DE, Loscalzo J. Adenosine-dependent induction of glutathione peroxidase 1 in human primary endothelial cells and protection against oxidative stress. Circ Res. 2005;96:831-7.
17. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia. 2003;46:1153-60.
18. Roa H, Gajardo C, Troncoso E, Fuentealba V, Escudero C, Yanez A, et al. Adenosine mediates transforming growth factor-beta 1 release in kidney glomeruli of diabetic rats. FEBS Lett. 2009;583:3192-8.
19. Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol. 2005;167:315-25.
20. Vallon V, Osswald H. Dipyridamole prevents diabetesinduced alterations of kidney function in rats. Naunyn Schmiedebergs Arch Pharmacol. 1994;349:217-22.
21. Tagawa H, Vander AJ. Effects of adenosine compounds on renal function and renin secretion in dogs. Circ Res. 1970;26: 327-38.
22. Weihprecht H, Lorenz JN, Schnermann J, Skott O, Briggs JP. Effect of adenosine1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus. J Clin Invest. 1990;85:1622-8.
23. Albino-Teixeira A, Matias A, Polonia J, Azevedo I. Blockade of adenosine receptors causes hypertension and cardiovascular structural changes in the rat. J Hypertens Suppl. 1991; 9:S196-7.
24. Sousa T, Morato M, Albino-Teixeira A. Angiotensin converting enzyme inhibition prevents trophic and hypertensive effects of an antagonist of adenosine receptors. Eur J Pharmacol. 2002;441:99-104.
25. Morato M, Sousa T, Guimarães S, Moura D, Albino- Teixeira A. The role of angiotensin II in hypertension due to adenosine receptors blockade. Eur J Pharmacol. 2002;455: 135-41.
26. Sousa T, Pinho D, Morato M, Marques-Lopes J, Fernandes E, Afonso J, et al. Role of superoxide and hydrogen peroxide in hypertension induced by an antagonist of adenosine receptors. Eur J Pharmacol. 2008;588:267-76.
27. Patinha D, Fasching A, Pinho D, Albino-Teixeira A, Morato M, Palm F. Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors. Am J Physiol Renal Physiol. 2013;304:F614-22.
28. Sousa T, Oliveira S, Afonso J, Morato M, Patinha D, Fraga S, et al. Role of H(2) O(2) in hypertension, renin-angiotensin system activation and renal medullary disfunction caused by angiotensin II. Br J Pharmacol. 2012;166: 2386-401.
29. Shiono K, Sokabe H. Renin-angiotensin system in spontaneously hypertensive rats. Am J Physiol. 1976;231:1295-9.
30. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol. 1999;10:2382-91.
31. Cassis LA. Downregulation of the renin-angiotensin system in streptozotocin-diabetic rats. Am J Physiol. 1992;262:E105-9.
32. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005; 16:2073-80.
33. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. 2002;61:186-94.
34. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39:269-74.
35. Kobori H, Katsurada A, Miyata K, Ohashi N, Satou R, Saito T, et al. Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA. Am J Physiol Renal Physiol. 2008;294:F1257-63.
36. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension. 2003;41:42-9.
37. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61:579-85.
38. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009;53:344-50.
39. Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26:170-7.
40. Urushihara M, Kondo S, Kagami S, Kobori H. Urinary angiotensinogen accurately reflects intrarenal reninangiotensin system activity. Am J Nephrol. 2010;31: 318-25.
41. Pawlowska D, Granger JP, Knox FG. Effects of adenosine infusion into renal interstitium on renal hemodynamics. Am J Physiol. 1987;252:F678-82.
42. Moreira-Rodrigues M, Quelhas-Santos J, Serrao P, Fernandes-Cerqueira C, Sampaio-Maia B, Pestana M. Glycaemic control with insulin prevents the reduced renal dopamine D1 receptor expression and function in streptozotocin-induced diabetes. Nephrol Dial Transplant. 2010;25:2945-53.
43. Lee HT, Emala CW. Adenosine attenuates oxidant injury in human proximal tubular cells via A(1) and A(2a) adenosine receptors. Am J Physiol Renal Physiol. 2002;282:F844-52.
44. Wu L, Juurlink BH. The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 2001;19: 1819-25.
45. Lee SK, Arunkumar S, Sirajudeen KN, Singh HJ. Glutathione system in young spontaneously hypertensive rats. J Physiol Biochem. 2010;66:321-7.
46. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension. 2000;36:142-6.
47. Rybka J, Kupczyk D, Kedziora-Kornatowska K, Motyl J, Czuczejko J, Szewczyk-Golec K, et al. Glutathione-related antioxidant defense system in elderly patients treated for hypertension. Cardiovasc Toxicol. 2011;11:1-9.
48. Jackson EK. Adenosine: a physiological brake on renin release. Annu Rev Pharmacol Toxicol. 1991;31:1-35.
49. Ohnishi A, Biaggioni I, Deray G, Branch RA, Jackson EK. Hemodynamic effects of adenosine in conscious hypertensive and normotensive rats. Hypertension. 1986;8:391-8.
50. Ramkumar N, Kohan DE. Proximal tubule angiotensinogen modulation of arterial pressure. Curr Opin Nephrol Hypertens. 2013;22:32-6.
51. Faulhaber-Walter R, Jou W, Mizel D, Li L, Zhang J, Kim SM, et al. Impaired glucose tolerance in the absence of adenosine A1 receptor signaling. Diabetes. 2011;60:2578.
52. Awad AS, Rouse M, Liu L, Vergis AL, Rosin DL, Linden J, et al. Activation of adenosine 2A receptors preserves structure and function of podocytes. J Am Soc Nephrol. 2008; 19:59-68.
53. Zou AP, Nithipatikom K, Li PL, Cowley AW Jr. Role of renal medullary adenosine in the control of blood flow and sodium excretion. Am J Physiol. 1999;276:R790-8.
54. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86:901-40.
55. Pflueger AC, Berndt TJ, Knox FG. Effect of renal interstitial adenosine infusion on phosphate excretion in diabetes mellitus rats. Am J Physiol. 1998;274:R1228-35.